

**AMENDMENTS TO THE SPECIFICATION**

5           Please replace paragraph (00035) with the following amended paragraph:

(00035)       Other embodiments include a method to enhance the expression of one or more cytokines or interleukins that facilitate Th1 immune responses in a subject or to reduce the expression of one or more cytokines or interleukins that  
10   facilitate Th2 immune response in a subject comprising administering to the subject an effective amount of the composition of claim 32, whereby the subject's Th1 immune response is enhanced ~~or~~ or the subject's undesired Th2 immune response is reduced.

15           Please replace paragraph (000148) with the following amended paragraph:

(000148)   Other embodiments include compounds compositions and formulations where one or more of  $R^1$ - $R^6$ ,  $R^{10}$ ,  $R^{15}$ ,  $R^{17}$  and  $R^{18}$  comprise an  
20   amino acid or a peptide, e.g.,  $R^1$ ,  $R^2$  or  $R^4$  comprises an amino acid or a peptide,  $R^3$  is a halogen and  $R^5$  and  $R^6$  are both  $-CH_3$ . The peptide at one or more of  $R^1$ - $R^6$  can comprise a cell surface binding peptide such as the entire protein or a sequence from fibronectin or retronectin, e.g., KQAGDV (SEQ ID NO 1).

25           Please replace paragraph (000202) with the following amended paragraph:

(000202)   **Groups 37-1 through 37-25-10-6.** These groups comprise each compound named in all of the ~~compound~~-compound groups 1 through 36-25-10-  
30   6 described above wherein  $R^1$  is not divalent, e.g., is not  $=O$ , and it is in the  $\alpha$ -configuration, instead of the  $\beta$ -configuration as shown in formula B.